Acadia Pharmaceuticals Inc.

Company Website

3911 Sorrento Valley Blvd.
San Diego, CA 92121

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Acadia Pharmaceuticals Inc.

Market Cap as of 6/12/2015

$3,989,831,680

Market Cap as of 7/03/2014

$2,339,800,346

Market Cap as of 07/02/2013

$1,590,568,237

Market Cap as of 06/26/2012

$81,772,400

Market Cap as of 01/04/2012

$57,553,010

Market Cap as of 06/20/2011

$84,859,020

Market Cap as of 01/06/2011

$46,766,170

Exchange and Ticker Symbol

Nasdaq: ACAD

Fields of Research

Focuses on drug discovery and clinical development of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders

Major Products

Pimavanserin, Alpha adrenergic agonists, Muscarinic agonist, AM-831

View all the companies in San Diego Publicly Traded Companies

Acadia Pharmaceuticals Inc.

Market Cap as of 6/12/2015

$3,989,831,680

Exchange

NASDAQ

Ticker

ACAD

Executives

Uli Hacksell

  • Chief Executive Officer
  • President